1st announcement

abstract submission deadline: 9 November 2018

9th European Multidisciplinary Colorectal Cancer Congress

9-11 March 2019

Lisbon Congress Center

Portugal

www.emccc2019.org
WELCOME

We are delighted to invite you to the 9th European Multidisciplinary Colorectal Cancer Congress 2019!

The European Multidisciplinary Colorectal Cancer Congress (EMCCC) is the European conference that truly provides a platform for in-depth multidisciplinary interaction among the various research areas involved. The Dutch Colorectal Cancer Group (DCCG) has taken the initiative for the EMCCC since 2001. The conference in 2019 builds upon eight previous successful multidisciplinary conferences on colorectal cancer which were held in the Netherlands, Germany and France. The EMCCC offers an intimate scientific/educational environment for more than 700 participants.

Colorectal cancer is one of the most common types of malignancies and much progress has been made in recent years in understanding the biology and treatment of this disease. These developments encompass almost the full research area including genetics, biology, pathology/prognostic markers, surgery, screening, systemic treatment, radiotherapy, and imaging. This implies that both pre-clinical and clinical research is becoming much more multidisciplinary oriented. The conference will have separate workshops on surgery, medical oncology, radiotherapy, pathology, imaging, gastroenterology, and genetics, but all other sessions are plenary in order to have optimal interaction between all disciplines. The format of the conference consists of workshops, keynote lecture, controversy sessions, satellite symposia, and oral and poster presentations on prevention and screening, diagnosis and follow-up, translational research, multidisciplinary management, genetics, evaluation of treatment, and updates on randomized CRC trials.

The meeting will be hosted in the Lisbon Congress Center, Lisbon, Portugal from 9 March until 11 March 2019.

We look forward to greeting you in Portugal!

EMCCC 2019 Organizing committee

Dirk Arnold (Medical Oncology, EORTC)
Regina Beets-Tan (Radiology, DCCG)
Jeroen Buyesen (Radiotherapy, DCCG)
Miriam Koopman (Medical Oncology, DCCG)

Helder Mansinho (Medical Oncology, GICD)
Leon Moons (Gastroenterology, DCCG)
Rolf Sijmons (Genetics, DCCG)
Pieter Tanis (Surgery, DCCG)

IMPORTANT DATES
- 9 November 2018 Abstract deadline
- 1 December 2018 Abstract letters of acceptance will be sent
- 1 December 2018 Deadline Early bird registration fee
- 15 January 2019 Deadline Late breaking abstracts
- 14 February 2019 Deadline Regular registration fee

CONGRESS DETAILS

SCIENTIFIC COMMITTEE
Richard Adams (Medical Oncology, UK)
Ane Appelt (Radiotherapy, UK)
Geerard Beets (Surgery, the Netherlands)
Luis Costa (Medical Oncology, Portugal)
Karen Lise Garm Spindler (Clinical Oncology, Denmark)
Thomas Helmerberger (Interventional Radiology, Switzerland)
Sara Lonardi (Medical Oncology, Italy)
Teresa Macarulla (Medical Oncology, Spain)
Anna Martling (Surgery, Sweden)
Marc Peeters (Medical Oncology, Belgium)
Hugo Pinto Marques (Surgery, Portugal)
Sabine Tejpar (Medical Oncology, Belgium)
Kees Verhoef (Surgery, the Netherlands)
Hans de Wilt (Surgery, the Netherlands)

EMCCC 2019 IS AN INITIATIVE OF:

Dutch Colorectal Cancer Group (DCCG)
European Organization for Research and Treatment of Cancer GastroIntestinal Tract Cancer Group (EORTC - GIC Group)
Grupo de Investigaciones De Cancro Digestivo (GICD)

THE 9TH EMCCC IS ENDORSED BY:

CONGRESS & EXHIBITION ORGANIZERS

Congress Care
PO Box 440
5201 AK ’s-Hertogenbosch
The Netherlands
Tel. +31-73-690 1415
emccc@congresscare.com
www.congresscare.com
CALL FOR ABSTRACTS

Abstract deadline
Friday 9 November 2018, 10.00hrs. CET (Central European Time)
The EMCCC Scientific Committee would like to encourage authors to submit their abstracts through the congress website. The online submission module is available at: www.emccc2019.org. Please check the conference website for the submission guidelines and read them carefully before submitting your abstract.

Late breaker abstracts
Late breaker abstracts will only be considered if there is new information on surgery, medical oncology, radiotherapy, pathology, imaging, gastroenterology, and genetics that should be brought to the attention of conference because it is timely and will likely have an impact on the conference topics and the CRC community at large. Late breaking abstracts can be sent until 15 January 2019. Information on submission will be published as of 9 November 2018.

Important dates for authors
9 November 2018 Abstract submission deadline
1 December 2019 Abstract letters of acceptance will be sent
15 January 2019 Deadline late breaking abstracts
1 February 2019 Abstract presenter registration deadline

PRELIMINARY PROGRAM

SATURDAY 9 MARCH 2019

13:00 Opening
13:05 Lessons to be learned from national and international CRC research infrastructures
Dutch T1 CRC working group
French GRECCAR Study Group
Centre for trials research, Cancer trials
Danish Colorectal Cancer Group
Dutch Colorectal Cancer Group
Italian Intergroup structure and projects
German AIO group
Spanish TTD Group
Portuguese GICD study group
EORTC GI group
Discussion
14:30 Break
15:00 Sponsored Symposium
16:00 Discussing areas of controversy: What is now known and established, and where are the major unmet needs?
In locoregional treatment of rectal cancer
In locoregional treatment of colon cancer
In local treatments of metastases:
- Surgery
- Interventional radiology
- Radiotherapy
In systemic treatment
18:00 DCCG lecture: Colon cancer: What is the best approach to understand the disease?
19:00 Welcome reception
SUNDAY 10 MARCH 2019

08:15  Session 1: Challenges in screen detected early cancers
Prediction models for lymph node metastases
Evaluation of the resection margin - is 1mm sufficient?
What is coming next in the prediction of lymphnode metastases
Discussion

09:30  Session 2: What’s new in diagnostic imaging – and what are the therapeutic consequences?
Locoregional staging of colon and rectal cancer
Imaging modalities for liver metastases
New diagnostic tools: Radiomics, “deep learning” – really helpful?
Discussion

10:45  Break

11:15  Session 3: Controversies in preoperative treatment
Difference between cCR after CRT for advanced rectal cancer and aiming for cCR with CRT in “no advanced rectal cancer”.
Is chemotherapy going to replace radiotherapy in rectal cancer?
Deciding on further local treatment after induction therapy for local and metastatic disease; value and timing of re-staging modalities
Discussion

12:30  Lunch and poster viewing

12:45  CRC Group Meetings / Trial Meetings / Consensus or Guideline initiatives
InterAACT: A global initiative in anal cancer
Translational research peritoneal metastases DCCG/DPOG

12:45  Sponsored Symposium

14:00  Session 4: Case discussion with expert panel
Case on the edge of liver surgery for mCRC
Case on the edge of multimodality treatment of mCRC

15:00  Session 5: Translational research: From markers to decisions
Clinical implications of “liquid” markers (ctDNA) for treatment selection and response evaluation
Clinical implications of tissue-based markers (CMS and others)
Organoids to assess treatment response

16:00  Break

16:30  Session 6: What’s new in diagnostic and therapeutic endoscopy?
State of the art optical diagnosis of polyps
Endoscopic and surgical techniques for local excision in rectal cancer, what should we do?
Endoscopic and hybrid techniques for local excision of colon cancer
Discussion

19:00  Dinner event
Monday 11 March 2019

08:15 Session 7: Future of primary rectal cancer treatment
Role of external boost and brachytherapy in rectal cancer
Challenges in rectal cancer surgery: which problems have to be solved?
Locally recurrent rectal cancer; multimodality approach
Discussion

09:30 Session 8: Systemic therapy in the metastatic setting – state of the art and future
Targeting RAS mutated tumors
Prognostic/predictive value of molecular and clinical factors: What makes the difference?
Optimal strategy to convert CRCLM into resectable disease; CAIRO5
Discussion

10:45 Break

11:15 Session 9: Colorectal cancer and the immune system
What are the new drugs in the field of immunotherapy?
What are the diagnostic tools and novel concepts of cancer evolution?
What are the effects that are interfering with local or current treatments?
Discussion

12:30 Lunch and poster viewing

12:45 Sponsored Symposium

12:45 CRC Group Meetings / Trial Meetings / Consensus or Guideline initiatives
Prospective Dutch CRC cohort (PLCRC): Nationwide infrastructure for colorectal cancer research in the Netherlands
Presentation of CIREL and CIEMAR registries

12:45 Best abstracts

14:00 Session 10: Genetics
Update: the genetic differential diagnosis of polyposis and CRC
Predicting CRC risk: from tumor syndromes genes to polygenic risk scores
Chemoprevention and vaccines for hereditary CRC
Discussion

15:15 Break

Session 11: Curative treatment of metastases
Controversies in loco-regional therapy of peritoneal metastases: What is really needed?
Liver-directed therapies (Hepatic arterial infusion, SIRT): What to use when?
Spectrum of treatments for lung metastases: SBRT, RFA, resection or no local therapy at all?
Discussion

17:00 Closing and drinks
GENERAL INFORMATION

Registration & Hotel accommodation

<table>
<thead>
<tr>
<th></th>
<th>Early Bird (until 1 Dec. ’18)</th>
<th>Regular (Until 14 Feb.’19)</th>
<th>Late (from 15 Feb. ’19 and on-site)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians &amp; academics</td>
<td>EUR 495</td>
<td>EUR 695</td>
<td>EUR 795</td>
</tr>
<tr>
<td>Physicians &amp; academics in training*</td>
<td>EUR 325</td>
<td>EUR 425</td>
<td>EUR 495</td>
</tr>
<tr>
<td>Emerging Economy Rate**</td>
<td>EUR 175</td>
<td>EUR 200</td>
<td>EUR 200</td>
</tr>
<tr>
<td>Day-registration</td>
<td>EUR 300</td>
<td>EUR 300</td>
<td>EUR 350</td>
</tr>
</tbody>
</table>

Conditions:
* Physicians/scientists in training have to provide a written certification by the head of department.
** Emerging Economy Rate is applied to individuals (no group registrations) from low-income and lower-middle-income economies according to the World Bank listing. Please see detailed information on the website.

Welcome reception
On Saturday 09 March 2019 the welcome reception will take place at the Lisbon Congress Center, from 18:30 – 19:30 hrs. The welcome reception is included in the conference fee.

Congress dinner
The congress dinner will be at the Páteo Alfacinha on Sunday 10 March 2019, from 18:00hrs. A dinner ticket can be purchased during the registration, at EUR 75 per person, including a 3-course dinner and bus transfer.

What is included in the registration fee?
Admission to all scientific sessions and the industrial exhibition, welcome reception, final program, certificate of attendance, 2 lunches and coffee breaks.

Group registrations
For group registrations; please contact the congress secretariat via: emccc@congresscare.com.

Cancellation
Cancellations made before 11 January 2019 will be refunded less 30% to cover administration costs. After this date no refunds will be given. All refunds will be made after the congress.

Hotel accommodation
The Organization of the EMCCC 2019 has secured, through the Housing Bureau – Mondial & Cititravel Congressos -, a number of rooms in several hotels located near the Congress venue and the city center. Please see detailed information on the website.

Congress venue
Lisboa Congress Center
Praça das Indústrias nº1
1300-307, Lisbon
Portugal

Target audience
Health care professionals, working in the field of colorectal cancer with an interest in: medical oncology, surgical oncology, radiation oncology, pathology, gastroenterology, imaging, radiology, basic science and genetics. Delegates attending EMCCC congresses originate from all over the world.

Timing
The congress will start on Saturday 9 March 2019 at 13:00 hrs and ends Monday 11 March 2019 at 17:00 hrs so that everybody can take the European evening flights.

Language
The official congress language will be English. No simultaneous translation will be available.

Liability and insurance
In registering for the 9th European Multidisciplinary Colorectal Cancer Congress delegates agree that neither the organization nor the congress secretariat Congress Care is responsible for individual medical, travel or personal insurance. Delegates are requested to arrange their own travel and health insurance. The organizers cannot assume liability for changes in the program due to external circumstances.

CME Accreditation
Accreditation for the 9th European Multidisciplinary Colorectal Cancer Congress is applied at the European Accreditation Council for Continuing Medical Education (EACCME). This accreditation will be endorsed by the European Union of Medical Specialists (UEMS) ensuring that the CME credits awarded to the participants are recognized by the national medical authorities who have agreed to co-operate in this European system. EACCME credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA).

The previous edition was granted with 15 hours of European external CME credits.